Close Menu

NEW YORK (GenomeWeb) – Veracyte announced today that it has priced a public offering of 5 million shares of its common stock at $6 per share, for gross proceeds of $30 million.

The offering’s underwriters have also been granted a 30-day option to buy an additional 750,000 shares at the public offering price, minus underwriting discounts and commissions.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jun
13

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type. 

Jun
18
Sponsored by
ArcherDX

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 

Jun
19

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.